Brief: Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan
25/03/2025 08:03
March 25 (Reuters) - Alumis Inc ALMS.O: ALUMIS AND KAKEN PHARMACEUTICAL ANNOUNCE COLLABORATION AND LICENSING AGREEMENT FOR ESK-001 IN DERMATOLOGY IN JAPAN ALUMIS INC - TO RECEIVE $40 MILLION UPFRONT, POTENTIAL $140 MILLION IN MILESTONE PAYMENTS Source text: ID:nGNX1yGWLl Further company coverage: ALMS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial